NEXT Financial Group Inc Increases Holdings in Eli Lilly and Company (NYSE:LLY)

NEXT Financial Group Inc increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 16.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,185 shares of the company’s stock after purchasing an additional 1,426 shares during the period. NEXT Financial Group Inc’s holdings in Eli Lilly and were worth $2,353,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in LLY. Ironwood Wealth Management LLC. boosted its position in Eli Lilly and by 2.5% in the 1st quarter. Ironwood Wealth Management LLC. now owns 4,690 shares of the company’s stock valued at $876,000 after buying an additional 114 shares during the last quarter. Sierra Capital LLC acquired a new stake in Eli Lilly and during the 1st quarter valued at approximately $46,000. Geneos Wealth Management Inc. grew its stake in Eli Lilly and by 1.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 13,525 shares of the company’s stock valued at $2,472,000 after purchasing an additional 246 shares in the last quarter. Corsicana & Co. purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $46,000. Finally, Salvus Wealth Management LLC purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $209,000. 81.56% of the stock is owned by hedge funds and other institutional investors.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 21,369 shares of the business’s stock in a transaction on Wednesday, October 27th. The stock was sold at an average price of $252.33, for a total transaction of $5,392,039.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

NYSE:LLY opened at $260.37 on Friday. Eli Lilly and Company has a 12-month low of $143.13 and a 12-month high of $275.87. The firm has a market capitalization of $249.07 billion, a P/E ratio of 39.69, a P/E/G ratio of 2.06 and a beta of 0.32. The company has a debt-to-equity ratio of 1.95, a current ratio of 1.30 and a quick ratio of 1.02. The business has a 50 day simple moving average of $246.14 and a 200 day simple moving average of $238.86.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Monday, October 25th. The company reported $1.94 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.98 by ($0.04). Eli Lilly and had a net margin of 21.52% and a return on equity of 111.51%. The company had revenue of $6.77 billion for the quarter, compared to analyst estimates of $6.64 billion. During the same quarter in the prior year, the firm earned $1.54 EPS. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 8.06 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 10th. Shareholders of record on Monday, November 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Friday, November 12th. This represents a $3.40 dividend on an annualized basis and a yield of 1.31%. Eli Lilly and’s dividend payout ratio (DPR) is presently 51.83%.

LLY has been the topic of several analyst reports. Truist Securities lifted their price objective on Eli Lilly and from $262.00 to $301.00 and gave the stock a “buy” rating in a report on Wednesday. DZ Bank upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $288.00 price objective on the stock in a report on Thursday, August 5th. Citigroup upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $210.00 to $265.00 in a report on Wednesday, September 29th. They noted that the move was a valuation call. Morgan Stanley lifted their price objective on Eli Lilly and from $207.00 to $275.00 and gave the stock an “overweight” rating in a report on Wednesday, August 4th. Finally, Truist lifted their target price on Eli Lilly and from $262.00 to $301.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $271.11.

Eli Lilly and Company Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Featured Article: What is the Book Value of a Share?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.